# Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer

> **NCT03750916** · PHASE2 · UNKNOWN · sponsor: **Qilu Hospital of Shandong University** · enrollment: 46 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib Hydrochloride plus Docetaxel

## Key facts

- **NCT ID:** NCT03750916
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-30
- **Primary completion:** 2020-11-30
- **Final completion:** 2020-11-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2018-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03750916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03750916, "Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03750916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*